Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Aug;27(8):4387-4400.
doi: 10.1111/dom.16476. Epub 2025 May 19.

Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta-analysis

Nawal Alammari  1 , Atheel Alshehri  1 , Abdulhameed Al Khalaf  2 , Rahaf Abdulaziz Alamri  1 , Noor Alhalal  3 , Majd Abdullah Sultan  1 , Nesreen Ogran  1 , Razan Mubarak S Aljohani  4 , Sarah Mohammed Saad Alasmari  1 , Sarah Badr Alsharif  5 , Zainah Al-Qahtani  6 , Ahmed Y Azzam  7
Affiliations
Meta-Analysis

Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta-analysis

Nawal Alammari et al. Diabetes Obes Metab. 2025 Aug.

Abstract

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardiovascular benefits beyond glycemic control, but the benefits of protection across cerebrovascular and cardiovascular territories remain incompletely studied in the literature. We aim to evaluate whether GLP-1 RAs provide balanced protection against stroke and myocardial infarction (MI) and identify factors that modify this protection.

Methods: We conducted a systematic review and meta-analysis of randomised controlled trials comparing GLP-1 RAs with placebo that reported cerebrovascular and cardiovascular outcomes. We calculated hazard ratios (HRs) for stroke and MI and developed a novel Territorial Benefit Ratio (TBR = HR stroke/HR MI) to quantify relative cerebrovascular versus coronary protection. Meta-regression analyses identified factors modifying territorial protection.

Results: Eleven trials with 85 373 participants met inclusion criteria. GLP-1 RAs significantly reduced stroke (HR 0.88, 95% CI 0.80-0.96) and MI (HR 0.87, 95% CI 0.79-0.97), resulting in an overall balanced TBR of 1.01 (95% CI 0.89-1.15). Protection patterns varied significantly by patient subgroups: prior stroke history provided better stroke protection (HR 0.73, NNT 54), while prior MI history provided better MI protection (HR 0.79, NNT 55). MI protection emerged earlier within the first six months (HR 0.81), while stroke protection strengthened over time (over 24 months: HR 0.80). Renal dysfunction, atrial fibrillation, and hypertension shifted protection towards stroke, while dyslipidemia provided better MI protection.

Conclusions: GLP-1 RAs demonstrate a protection-in-territory-at-risk pattern with important temporal findings and results translated. These findings support a personalised approach to GLP-1 RA therapy that considers patients' vascular history and risk profiles. The earlier emergence of MI protection and later strengthening of stroke protection deliver significant highlights for clinical expectations and treatment persistence.

Keywords: GLP‐1 RA; cardiovascular disease; cerebrovascular disease; myocardial infarction; stroke.

PubMed Disclaimer

References

REFERENCES

    1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon‐like Peptide‐1. Cell Metab. 2018;27(4):740‐756.
    1. Hamed K, Alosaimi MN, Ali BA, et al. Glucagon‐like Peptide‐1 (GLP‐1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus. 2024;16(9):e68390.
    1. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP‐1 receptor agonists in patients with type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776‐785.
    1. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2018;72(24):3200‐3223.
    1. Sposato LA, Hilz MJ, Aspberg S, et al. Post‐stroke cardiovascular complications and neurogenic cardiac injury: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2020;76(23):2768‐2785.

MeSH terms

Substances

LinkOut - more resources